^
BRCA2 mutation
Peritoneal Cancer
BGB-290
Sensitive
:
A1
BeiGene Press Release - 1d
BRCA1 mutation
Peritoneal Cancer
BGB-290
Sensitive
:
A1
BeiGene Press Release - 1d
No biomarker
Peritoneal Cancer
olaparib + bevacizumab
Sensitive
:
A2
NICE - 1wk
HRD
Peritoneal Cancer
olaparib + bevacizumab
Sensitive
:
A1
NICE - 1wk
No biomarker
Peritoneal Cancer
niraparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
olaparib + bevacizumab
Sensitive
:
A1
No biomarker
Peritoneal Cancer
bevacizumab
Sensitive
:
A1
No biomarker
Peritoneal Cancer
rucaparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
olaparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
Mvasi (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Peritoneal Cancer
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Peritoneal Cancer
Onbevzi (bevacizumab biosimilar)
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
rucaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
rucaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
olaparib + bevacizumab
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
niraparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
niraparib
Sensitive
:
A1
HRD
Peritoneal Cancer
niraparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
olaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
olaparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
carboplatin + micellar paclitaxel
Sensitive
:
A1
No biomarker
Peritoneal Cancer
Bevax (bevacizumab biosimilar)
Sensitive
:
A1
MSI-H/dMMR
Peritoneal Cancer
pembrolizumab
Sensitive
:
A2
No biomarker
Peritoneal Cancer
BEP
Sensitive
:
A2
TMB-H
Peritoneal Cancer
pembrolizumab
Sensitive
:
A2
No biomarker
Peritoneal Cancer
EP
Sensitive
:
A2
No biomarker
Peritoneal Cancer
VAC
Sensitive
:
A2
No biomarker
Peritoneal Cancer
IP
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our